Last updated: July 12, 2026
Tanabe Pharma Corporation sued Azurity Pharmaceuticals, Inc. in E.D. Texas under case number 1:26-cv-00069. The docket-level record provided here is insufficient to produce a complete, citation-grade litigation summary (claims asserted, asserted patents, paragraph IV allegations, remedies sought, procedural posture, and any stay/settlement/disposition).
What patents are asserted in Tanabe Pharma v. Azurity (1:26-cv-00069)?
Answer: Not determinable from the information available in this prompt.
Which Orange Book listed drugs and listed patents are in-suit?
Answer: Not determinable from the information available in this prompt.
Are the asserted theories Paragraph IV, 505(b)(2), or reformulation/combination patents?
Answer: Not determinable from the information available in this prompt.
What is the procedural posture of case 1:26-cv-00069?
Answer: Not determinable from the information available in this prompt.
Has Azurity moved to dismiss or for summary judgment?
Answer: Not determinable from the information available in this prompt.
Have claim construction events occurred?
Answer: Not determinable from the information available in this prompt.
Has the case been stayed pending PTAB or FDA exclusivity?
Answer: Not determinable from the information available in this prompt.
What is the litigation timeline for Tanabe v. Azurity?
Answer: Not determinable from the information available in this prompt.
Complaint filing date, responsive pleading date, and service milestones
Answer: Not determinable from the information available in this prompt.
Any scheduled hearing dates, trial dates, or ADR deadlines
Answer: Not determinable from the information available in this prompt.
What claims does Tanabe allege and what relief does it seek?
Answer: Not determinable from the information available in this prompt.
Injunctive relief and damages exposure
Answer: Not determinable from the information available in this prompt.
Facts tied to FDA submissions (ANDA, 505(b)(2), section 505(j) notice)
Answer: Not determinable from the information available in this prompt.
How does Paragraph IV risk analysis apply to Tanabe’s case?
Answer: Not determinable from the information available in this prompt.
Does Azurity’s filing trigger an automatic 30-month stay?
Answer: Not determinable from the information available in this prompt.
Is a Section viii/Chapter IV settlement agreement implicated?
Answer: Not determinable from the information available in this prompt.
What is the strength of Tanabe’s asserted patent estate in this case?
Answer: Not determinable from the information available in this prompt.
Patent filing and expiration fundamentals (utility, formulation, method-of-use)
Answer: Not determinable from the information available in this prompt.
Status signals: prosecution history, reexams, terminal disclaimers, PTAB challenges
Answer: Not determinable from the information available in this prompt.
What arguments is Azurity likely using to contest infringement and validity?
Answer: Not determinable from the information available in this prompt.
Non-infringement themes (label carve-outs, design-arounds, component substitutions)
Answer: Not determinable from the information available in this prompt.
Validity themes (anticipation, obviousness, §101, §112, indefiniteness)
Answer: Not determinable from the information available in this prompt.
How do motions and claim construction decisions typically change outcomes here?
Answer: Not determinable from the information available in this prompt.
Impact of Markman rulings on infringement models
Answer: Not determinable from the information available in this prompt.
Impact of novelty/obviousness framing on trial strategy
Answer: Not determinable from the information available in this prompt.
What settlement and licensing outcomes are possible under Hatch-Waxman practice?
Answer: Not determinable from the information available in this prompt.
Likelihood of a covenant-not-to-sue or stipulated injunction
Answer: Not determinable from the information available in this prompt.
Cross-licenses vs. product-launch timing structures
Answer: Not determinable from the information available in this prompt.
What generic entry risks exist for the relevant Tanabe product if Azurity prevails?
Answer: Not determinable from the information available in this prompt.
Launch design constraints driven by the asserted patents
Answer: Not determinable from the information available in this prompt.
Expected FDA approval pathway impact on design-arounds
Answer: Not determinable from the information available in this prompt.
Key Takeaways
- The case caption and docket number (Tanabe Pharma Corporation v. Azurity Pharmaceuticals, Inc., 1:26-cv-00069) identify the dispute, but the prompt does not include docket documents or asserted-patent details required for an accurate litigation summary.
- A litigation-grade analysis depends on the asserted patents, the FDA submission linkage (if any), the relief sought, and the procedural milestones, none of which are present in the provided information.
FAQs
- What E.D. Texas judge is assigned to 1:26-cv-00069 and what impact does that have on schedule?
Not determinable from the information available in this prompt.
- Which Tanabe Orange Book patents does the complaint target in 1:26-cv-00069?
Not determinable from the information available in this prompt.
- Did Azurity file a Paragraph IV certification, and what is the 30-month stay status?
Not determinable from the information available in this prompt.
- Have any PTAB challenges been filed against the asserted patents?
Not determinable from the information available in this prompt.
- Is there a reported settlement or covenant-not-to-sue tied to 1:26-cv-00069?
Not determinable from the information available in this prompt.
References
- Tanabe Pharma Corporation v. Azurity Pharmaceuticals, Inc., Case No. 1:26-cv-00069 (E.D. Texas).
